Table 1: Baseline characteristics of MrOS Participants by Actigraphy-Determined Nocturnal Sleep Duration Group.
Results presented as N (%) or Mean ± SD as appropriate.
| Short Sleep Duration (<6h/night; N = 577) | Recommended Sleep Duration (7-8h/night; N = 478) | p-value | |
|---|---|---|---|
| Age (years) | 76.7 (5.6) | 76.5 (5.8) | 0.69 |
| Race/Ethnicity | |||
| Caucasian | 518 (89.8%) | 447 (93.5%) | 0.03 |
| African American | 23 (4.0%) | 8 (1.7%) | |
| Asian | 21 (3.6%) | 8 (1.7%) | |
| Hispanic | 13 (2.3%) | 10 (2.1%) | |
| Other | 2 (0.3%) | 5 (1.0%) | |
| Study Site | |||
| Birmingham | 80 (13.9%) | 78 (16.3%) | <0.001 |
| Minneapolis | 107 (18.5%) | 102 (21.3%) | |
| Palo Alto | 71 (12.3%) | 93 (19.5%) | |
| Pittsburgh | 142 (24.6%) | 66 (13.8%) | |
| Portland | 84 (14.6%) | 62 (13.0%) | |
| San Diego | 93 (16.1%) | 77 (16.1%) | |
| BMI (kg/m2) | 27.7 ± 4.0 | 26.3 ± 3.3 | <0.001 |
| Alcohol Drinks/Week | 1.7 ± 1.6 | 2.0 ± 1.6 | 0.008 |
| Osteoporosis | 21 (3.6%) | 15 (3.1%) | 0.66 |
| Calcium Use | 147 (25.5%) | 145 (30.3%) | 0.08 |
| Vitamin D Use | 359 (62.2%) | 310 (64.9%) | 0.38 |
| 25OHD Level (ng/mL) | 27.7 ± 8.4 | 29.7 ± 8.7 | <0.001 |
| Season of Vitamin D level | |||
| Winter | 179 (31.0%) | 162 (33.9%) | 0.04 |
| Spring | 149 (25.8%) | 105 (22.0%) | |
| Summer | 151 (26.2%) | 104 (21.8%) | |
| Fall | 98 (17.0%) | 107 (22.4%) | |
| History of Fracture | 26 (4.5%) | 18 (3.8%) | 0.55 |
| History of Falls | 187 (32.4%) | 129 (27.0%) | 0.06 |
| Hypertension | 267 (46.3%) | 222 (46.4%) | 0.96 |
| COPD | 28 (4.9%) | 15 (3.1%) | 0.16 |
| Depression | 34 (5.9%) | 26 (5.4%) | 0.74 |
| PASE Score | 149 ± 73 | 146 ± 72 | 0.51 |
| Health Quality | |||
| Excellent | 192 (33.3%) | 188 (39.3%) | 0.12 |
| Good | 323 (56.0%) | 236 (49.4%) | |
| Fair | 60 (10.4%) | 49 (10.3%) | |
| Poor | 1 (0.2%) | 4 (0.8%) | |
| Very Poor | 1 (0.2%) | 1 (0.2%) | |
| Testosterone Use | 6 (1.0%) | 3 (0.6%) | 0.47 |
| Androgen Deprivation Therapy Use | 7 (1.2%) | 2 (0.4%) | 0.16 |
| CRP Level (μg/mL) | 3.0 ± 5.1 | 2.6 ± 6.8 | 0.30 |
| eGFR (mL/min/1.73 m2) | 74.3 ± 16.6 | 72.1 ± 15.7 | 0.03 |
| Epworth Sleepiness Scale | 6.7 ± 3.8 | 5.3 ± 3.3 | <0.001 |
| Global PSQI Score | 5.9 ± 3.4 | 5.2 ± 3.2 | <0.001 |
| Taking a Sleep Medication | 71 (12.3%) | 49 (10.3%) | 0.30 |
| Melatonin Use | 7 (1.2%) | 10 (2.1%) | 0.26 |
| aMT6s Level (ng/mg Cr) | 10.2 ± 8.4 | 11.1 ± 8.5 | 0.11 |
| Sleep Duration (hours) | |||
| By Actigraphy | 5.1 ± 0.8 | 7.4 ± 0.3 | <0.001 |
| By Self-Report | 6.5 ± 1.2 | 7.2 ± 1.1 | <0.001 |
| Sleep Duration Needed to Feel Rested (hours) | 6.7 ± 1.1 | 7.3 ± 1.0 | <0.001 |
| Takes Naps Daily | 122 (21.1%) | 45 (9.4%) | <0.001 |
| Nap Duration by Actigraphy (minutes) | 54.9 ± 49.5 | 53.3 ± 51.2 | 0.62 |
| Nocturia | |||
| None | 31 (5.4%) | 21 (4.4%) | 0.54 |
| Once per Night | 170 (29.5%) | 149 (31.2%) | |
| Twice per Night | 193 (33.4%) | 141 (29.5%) | |
| Three or More Times per Night | 183 (31.7%) | 167 (34.9%) | |